This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .

CME Post-Test - Incretin Insider: Incretin Mimetics 2008 in Review

INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 70% or higher.

0. Have you created an account on WebBasedCME.com? You must register and be signed in to participate and receive CME credit for this activity.

1.	Compared with intravenous glucose, oral ingestion of glucose is associated with _______ insulin secretion.
A:		An increase in
B:		A decrease in
C:		Comparable
D:		Negligible

2.	The two key incretin hormones that have been shown to affect glucoregulation are:
A:		GLP-1 and GLP-2
B:		GIP-1 and GIP-2
C:		GLP-1 and GIP
D:		GIP and GLP-2

3.	Which of the following is NOT true of native GLP-1?
A:		It promotes insulin secretion in a glucose-dependent manner
B:		It suppresses glucagon secretion, independent of glucose levels
C:		It promotes β-cell mass in animal models
D:		It promotes satiety and weight loss

4.	Exenatide, a synthetic version of exendin-4 administered twice daily, has a ____% amino acid sequence homology with native GLP-1.
A:		33
B:		53
C:		73
D:		93

5.	A meta-analysis showed that twice daily exenatide reduced A1C by approximately ____%.
A:		0.5
B:		0.7
C:		1.0
D:		1.5

6.	A comparison of twice-daily exenatide and sitagliptin showed that reduction in postprandial glucose levels were:
A:		Greater with sitagliptin than with exenatide
B:		Greater with exenatide than with sitagliptin
C:		Comparable with exenatide and sitagliptin
D:		Negligible with both exenatide and sitagliptin

7.	The incretin mimetic liraglutide has a ____% amino acid sequence homology with native GLP-1.
A:		37
B:		57
C:		77
D:		97

8.	Results of the LEAD studies have demonstrated that 1.8 mg liraglutide once daily reduces A1C by approximately:
A:		0.5%-0.70%
B:		0.7%-0.9%
C:		0.9%-1.0%
D:		1.0%-1.5%

9.	Which of the following statements is NOT true with respect to the LEAD 6 study?
A:		Liraglutide was associated with a significantly greater decrease from baseline A1C compared with exenatide
B:		Liraglutide was associated with a significantly greater decrease in FPG compared with exenatide
C:		Exenatide was associated with a significantly greater reduction in weight compared with liraglutide
D:		The rates of nausea were similar between groups

10.	Compared with exenatide, exenatide LAR:
A:		Has a longer half-life
B:		Is associated with greater improvements in glycemic control
C:		Is associated with a lower incidence of nausea
D:		All of the above